Hu Lan-Dian, Zheng Guang-Yong, Jiang Hai-Song, Xia Yu, Zhang Yi, Kong Xiang-Yin
Health Science Center, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and Shanghai Second Medical University, Shanghai 200025, China.
Acta Pharmacol Sin. 2003 Aug;24(8):741-5.
Recently, more SARS-CoV virus genome sequences are released to the GenBank database. The aim of this study is to reveal the evolution forces of SARS-CoV virus by analyzing the nucleotide mutations in these sequences.
We obtained 20 SARS-CoV virus genome sequences from NCBI database, and calculated the ratio of non-synonymous nucleotide substitution per non-synonymous site (Ka) and synonymous nucleotide substitution per synonymous site (Ks) for SARS-CoV virus genes.
The Ka/Ks ratios for replicase polyprotein ORF1a, ORF1b, and spike protein gene are 1.09 (P=0.6501), 0.38 (P=0.0074), 0.65 (P=0.0685) respectively.
SARS-CoV virus replicase polyprotein ORF1b is undergoing negative selection; negative selection force is also probably operating on spike protein gene. These results provide basis for future developing a new drug and vaccine against SARS.
近期,更多严重急性呼吸综合征冠状病毒(SARS-CoV)病毒基因组序列被提交至GenBank数据库。本研究旨在通过分析这些序列中的核苷酸突变来揭示SARS-CoV病毒的进化驱动力。
我们从NCBI数据库获取了20条SARS-CoV病毒基因组序列,并计算了SARS-CoV病毒基因中每个非同义位点的非同义核苷酸替代率(Ka)和每个同义位点的同义核苷酸替代率(Ks)。
复制酶多聚蛋白ORF1a、ORF1b和刺突蛋白基因的Ka/Ks比值分别为1.09(P = 0.6501)、0.38(P = 0.0074)、0.65(P = 0.0685)。
SARS-CoV病毒复制酶多聚蛋白ORF1b正经历负选择;负选择力可能也作用于刺突蛋白基因。这些结果为未来开发抗SARS的新药和疫苗提供了依据。